Condition: Phenylketonuria, Maternal · Sponsor: BioMarin Pharmaceutical
This is a Phase 4 observational study designed to assess the impact of Palynziq ® (pegvaliase) treatment in pregnant women with PKU and on their offspring who were exposed to pegvaliase at any time during pregnancy and breastfeeding.
This description comes directly from the study's public registry record.
165-504 Program Director · 1-800-983-4587 · medinfo@bmrn.com
Always discuss trial participation with your own doctor first.
| Syneos Health | Wilmington, North Carolina, United States | Recruiting |
| Metabolics and Genetics in Calgary (MAGIC) | Calgary, Canada | Recruiting |
| Universitaetsklinikum Hamburg Eppendorf | Hamburg, Germany | Recruiting |
| Ospedale San Paolo | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05579548